studied head and neck cancer (NHC) and NSCLC patients using 89Zr-cetuximab PET/CT but showed that SUVmax and SUVmean had no direct relationship between EGFR immunohistochemistry (IHC) score and tumor-to-background ratio (TBR) (55). This evidence concerns the gene EGFR and non-small cell lung carcinoma.